User profiles for Tetsuhiro Harimoto
TETSUHIRO HARIMOTOHarvard University Verified email at g.harvard.edu Cited by 759 |
[HTML][HTML] A programmable encapsulation system improves delivery of therapeutic bacteria in mice
Living bacteria therapies have been proposed as an alternative approach to treating a
broad array of cancers. In this study, we developed a genetically encoded microbial …
broad array of cancers. In this study, we developed a genetically encoded microbial …
Enhancing the tropism of bacteria via genetically programmed biosensors
T Chien, T Harimoto, B Kepecs, K Gray… - Nature biomedical …, 2022 - nature.com
Engineered bacteria for therapeutic applications would benefit from control mechanisms
that confine the growth of the bacteria within specific tissues or regions in the body. Here we …
that confine the growth of the bacteria within specific tissues or regions in the body. Here we …
Zinc in depression: a meta-analysis
…, G Mazereeuw, K Goldberger, T Harimoto… - Biological …, 2013 - Elsevier
Background Zinc is an essential micronutrient with diverse biological roles in cell growth,
apoptosis and metabolism, and in the regulation of endocrine, immune, and neuronal functions …
apoptosis and metabolism, and in the regulation of endocrine, immune, and neuronal functions …
A rapid screening platform to coculture bacteria within tumor spheroids
T Harimoto, D Deb, T Danino - Nature protocols, 2022 - nature.com
The prevalence of tumor-colonizing bacteria along with advances in synthetic biology are
leading to a new generation of living microbial cancer therapies. Because many bacterial …
leading to a new generation of living microbial cancer therapies. Because many bacterial …
Bacterial therapies at the interface of synthetic biology and nanomedicine
Bacteria are emerging as living drugs to treat a broad range of disease indications. However,
the inherent advantages of these replicating and immunostimulatory therapies also carry …
the inherent advantages of these replicating and immunostimulatory therapies also carry …
Rapid screening of engineered microbial therapies in a 3D multicellular model
T Harimoto, ZS Singer, OS Velazquez… - Proceedings of the …, 2019 - National Acad Sciences
Synthetic biology is transforming therapeutic paradigms by engineering living cells and
microbes to intelligently sense and respond to diseases including inflammation, infections, …
microbes to intelligently sense and respond to diseases including inflammation, infections, …
Predictors of readmission to a psychiatry inpatient unit
J Moss, A Li, J Tobin, IS Weinstein, T Harimoto… - Comprehensive …, 2014 - Elsevier
Objective To determine predictors of time to readmission to a general psychiatry inpatient
unit. Method Data from the Minimum Data Set-Mental Health (MDS-MH), a standardized …
unit. Method Data from the Minimum Data Set-Mental Health (MDS-MH), a standardized …
[HTML][HTML] Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005–2012) compared to other international registries
B Paes, I Mitchell, A Li, T Harimoto… - Journal of Immunology …, 2013 - hindawi.com
Respiratory syncytial virus (RSV) infection occurs commonly in infants aged ≤2 years, and
severe infection results in hospitalization with accompanying morbidity and mortality. …
severe infection results in hospitalization with accompanying morbidity and mortality. …
Outcomes of infants receiving palivizumab prophylaxis for respiratory syncytial virus in Canada and Italy: an international, prospective cohort study
…, M Maule, E Girardi, T Harimoto… - The Pediatric …, 2017 - journals.lww.com
Background: Respiratory syncytial virus (RSV) infection frequently results in RSV-related
hospitalization (RSVH) in young infants. We examined the outcomes of palivizumab recipients …
hospitalization (RSVH) in young infants. We examined the outcomes of palivizumab recipients …
Risk factors for progression of Alzheimer disease in a Canadian population: the Canadian Outcomes Study in Dementia (COSID)
Objective: To determine risk factors for clinically significant progression during 12 months in
patients with mild-to-moderate Alzheimer disease. Method: Community-dwelling patients …
patients with mild-to-moderate Alzheimer disease. Method: Community-dwelling patients …